Tsujinaka, Kaito (K);Kanno, Marina (M);Ogawa, Atsushi (A);Kawada, Kei (K);Goda, Mitsuhiro (M);Uehara, Hisanori (H);Ishizawa, Keisuke (K);

Author information

Eur J Case Rep Intern Med.2025 Apr 18;12(5):005309.doi:10.12890/2025_005309

Abstract

BACKGROUND: Cytomegalovirus (CMV) colitis is a common complication in patients with ulcerative colitis (UC), which is often associated with immunosuppressive therapies including steroids, azathioprine, and biologics such as infliximab. Although CMV infections related to upadacitinib, a Janus kinase (JAK) inhibitor, have been reported, they typically occur after prolonged use. Consequently, early onset CMV colitis following the initiation of JAK inhibitors has not been extensively recognised.

CASE REPORT: We present the case of a 68-year-old Japanese woman with refractory UC who developed CMV colitis that initially improved but worsened shortly after starting upadacitinib. The patient improved following upadacitinib discontinuation and CMV-specific treatment. This case suggests that early onset CMV colitis after upadacitinib initiation is clinically significant and highlights the importance of monitoring lymphocyte counts and CMV antigen levels during JAK inhibitor therapy.

CONCLUSION: These findings provide valuable insights into the early risk of CMV reactivation and may guide future management strategies for patients with UC undergoing JAK inhibitor treatment.

LEARNING POINTS: This case provides insights into managing cytomegalovirus (CMV)-related adverse effects in patients receiving Janus kinase (JAK) inhibitors.The risk of CMV disease, including CMV colitis, should be considered owing to lymphocyte reduction during upadacitinib treatment.